Abstract
The phase III MPACT trial demonstrated the superiority of gemcitabine plus nab-paclitaxel (NABGEM) versus gemcitabine alone in previously untreated patients with metastatic pancreatic cancer (mPC). The aim of this study was to evaluate the responses in terms of efficacy and safety in patients treated with more than 6 cycles of chemotherapy. From January 2015 to December 2018, patients with mPC receiving first-line treatment with NABGEM were included in a multicentre retrospective observational study. Exploratory analyses of efficacy and safety were performed. The cohort included 153 patients with performance status of 1. The median overall survival and progression-free survival were 20 months (hazard ratio [HR] 0.28, 95% confidence interval [CI]: 0.17–0.44) and 10 months (HR 0.24 95% CI: 0.16–0.38) respectively, in patients who received >6 cycles compared to 9 and 5 months in those treated with ≤6 cycles (p < 0.001). The disease control rate was 100% versus 56% in patients receiving >6 and ≤6 cycles, respectively. No progression of disease was recorded in patients who received >6 cycles. Grade 1 neuropathy and grade 3 neutropenia were more frequent in patients treated with >6 cycles compared to patients receiving ≤6 cycles (p = 0.01; p = 0.03, respectively). Dose reduction was necessary for 70.1% and 53.4% of patients treated with >6 or ≤6 cycles, whereas treatment interruption occurred in 37.1% and 21.6%, respectively. Our results confirmed the efficacy and safety of NABGEM in untreated mPC. In particular, we highlighted significant clinical efficacy in patients who received >6 cycles of chemotherapy compared to those who received ≤6 cycles, with manageable toxicity profile.
Original language | English |
---|---|
Pages (from-to) | 753-759 |
Number of pages | 7 |
Journal | Journal of Chemotherapy |
Volume | 35 |
Issue number | 8 |
Early online date | 11 May 2023 |
DOIs | |
Publication status | Published - 31 Dec 2023 |
Data Availability Statement
The data used to support the findings of this study are available from the corresponding author upon request.Keywords
- efficacy and safety
- gemcitabine
- nab-paclitaxel
- Pancreatic cancer cycle
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases